Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 18/20 | 0.67 |
| ▸ | SRC | P12931 | 10/20 | 0.66 |
| ▸ | SYK | P43405 | 10/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300965 | 0.92 | GSK3A (0.67) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL16106395 | 0.92 | GSK3A (0.69) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL16138970 | 0.92 | GSK3A (0.67) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6546085 | 0.91 | GSK3A (0.68) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6298577 | 0.91 | GSK3A (0.66) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6298693 | 0.91 | GSK3A (0.71) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6300975 | 0.91 | GSK3A (0.66) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6305196 | 0.91 | MAPK14 (0.75) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6545988 | 0.89 | GSK3A (0.66) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6299895 | 0.89 | GSK3A (0.66) | GSK3ASRCSYKMAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981526-B1 | INTERMEDIATES USEFUL IN THE PREPARATION OF NAPHTHYLUREA DERIVATIVES USEFUL AS KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2021-11-03 | — | — | EP | disclosed |